sur Protagonist Therapeutics, Inc. (NASDAQ:PTGX)
Protagonist Therapeutics Recognized for Innovation in Biotech
Protagonist Therapeutics, a clinical-stage biopharmaceutical company, has been named one of the World's Most Innovative Companies for 2025 by Fast Company. Recognized for its advancements in peptide-based therapeutics, Protagonist stands out as a top biotechnology innovator.
The company's proprietary development platform has delivered significant candidates like Rusfertide, a potential treatment for polycythemia vera, and Icotrokinra, an oral IL-23 antagonist effective in psoriasis. Both drugs are advancing towards regulatory filings this year. Protagonist aims to provide oral solutions for conditions typically treated with injectables, addressing unmet needs in immunology and metabolic diseases.
Their achievements reflect a strategic focus on innovation and a solid financial foundation extending through 2028. Protagonist's inclusion in Fast Company's list underscores their commitment to pioneering transformative healthcare solutions.
R. E.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Protagonist Therapeutics, Inc.